drugset / Trial / NCT03002805
CBT-1® in Combination With Doxorubicin in Patients With Metastatic, Unresectable Sarcomas Who Previously Progressed on Doxorubicin
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study evaluates the combination of CBT-1® and doxorubicin for the treatment of metastatic, unresectable sarcoma in patients who have progressed after treatment with 150mg/m2 or less of doxorubicin. Participants will receive CBT-1® on days 1-7 of each 21-day cycle, as well as doxorubicin on days 5 and 6.
Timeline
- Start
- 2018-03-29
- Primary completion
- 2020-09
- Completion
- 2020-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CBT-1 | Small molecule | 50 mg/m2 | Oral |
| Subject | CBT-1 | Small molecule | 100 mg/m2 | Oral |
| Subject | CBT-1 | Small molecule | 150 mg/m2 | Oral |
| Subject | CBT-1 | Small molecule | 200 mg/m2 | Oral |
| Subject | CBT-1 | Small molecule | 250 mg/m2 | Oral |
| Subject | CBT-1 | Small molecule | 300 mg/m2 | Oral |
| Background | Doxorubicin | Other / unclassified | 37.5 mg/m2 | Intravenous |